Global RNA Therapy Market by Technology (Enabled Technologies, Enabling Technologies), Indication (Cancer, Cardiovascular, Genetic Disorders), End User - Forecast 2023-2030

The RNA Therapy Market size was estimated at USD 1.84 billion in 2022, USD 2.18 billion in 2023, and is expected to grow at a CAGR of 21.90% to reach USD 8.98 billion by 2030.

RNA therapy includes developing and commercializing therapeutic approaches that utilize ribonucleic acid (RNA) molecules to target specific genetic sequences and cellular mechanisms. These therapies treat various diseases and conditions by replacing faulty genes, silencing harmful gene expressions, or modulating cellular functions by targeting RNA molecules. Increasing investments in biotechnology startups, growing collaborations between academia and industry players, and an expanding portfolio of potential therapeutic targets for unmet medical needs drive the need for RNA therapies. Favorable regulatory policies for orphan drug designation and fast-track approvals have accelerated the clinical development of several RNA-based therapies. Delivery challenges associated with instability and rapid degradation of RNA molecules in vivo hampers market growth. Ongoing advancements by pharmaceutical companies to leverage cutting-edge technologies into novel RNA treatments for rare diseases with limited treatment options are expected to create opportunities for market growth.

Regional Insights

The RNA therapy market in the Americas is supported by a developed healthcare sector and supportive government programs, resulting in considerable commercialization of cutting-edge RNA therapies in the United States and Canada and the evolving pharmaceutical industry in South American countries. The governments in the Americas encourage technological advancements and research activities to provide a better healthcare system to people that contribute to overall economic growth and public welfare. The governments in the Asia-Pacific region's emerging and developed economies, such as Japan, India, China, and South Korea, encourage research and development of RNA therapies. Europe has significantly adopted RNA therapies owing to the rapid commercialization and acceptability of new devices and technologies, enabling healthcare professionals to use RNA therapies. On the other hand, the surging geriatric population in Europe is expected to increase the indication of several infectious and chronic disorders. As per the Population Reference Bureau (PRB), Russia, Germany, Italy, France, the UK, Spain, Turkey, Ukraine, Poland, Nigeria, and Iran are some countries that have a significant percentage of the population aged over 65 years. The rising indication of Europe's aging population and disorders necessitates efficient RNA therapies.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the RNA Therapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the RNA Therapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the RNA Therapy Market, highlighting leading vendors and their innovative profiles. These include Alnylam Pharmaceuticals, Inc., Arbutus Biopharma Corporation, Arcturus Therapeutics Holdings Inc., Arrowhead Pharmaceuticals, Inc., AstraZeneca PLC, Benitec Biopharma Limited, Biogen Inc., BioNTech SE, Cartesian Therapeutics, Inc., Cenix BioScience GmbH, Deep Genomics, Eli Lilly and Company, F. Hoffmann-La Roche AG, GSK PLC, Ionis Pharmaceuticals, Inc., Laronde, MiNA Therapeutics Limited, Moderna, Inc., NeuBase Therapeutics, Inc., Nordic Nanovector ASA, Novartis AG, Novo Nordisk A/S, Nutcracker Therapeutics, Inc., ProQR Therapeutics N.V., Sanofi S.A., Silence Therapeutics PLC, Sirnaomics, Inc., and Triplet Therapeutics, Inc.

Market Segmentation & Coverage

This research report categorizes the RNA Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Technology
  • Enabled Technologies
    • Inhibition
    • Labeling
    • Linear amplification
    • Microarrays
    • Purification
    • qRT-PCR
  • Enabling Technologies
    • RNA Antisense Technologies
      • MicroRNA
      • Small interfering RNA
    • RNA Interference Technologies
• Indication
  • Cancer
  • Cardiovascular
  • Genetic Disorders
  • Infectious Diseases
  • Kidney Diseases
  • Metabolic Disorders
  • Oncology
  • Retinal Diseases
• End User
  • Academic Research
  • Diagnostics
  • Drug Discovery & Development

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

The report offers valuable insights on the following aspects

1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

1. What is the market size and forecast of the RNA Therapy Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the RNA Therapy Market?
3. What are the technology trends and regulatory frameworks in the RNA Therapy Market?
4. What is the market share of the leading vendors in the RNA Therapy Market?
5. Which modes and strategic moves are suitable for entering the RNA Therapy Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.